HCPCS Level II code J9332 identifies the injectable biologic efgartigimod alfa-fcab at a 2 mg unit. As a drug-specific HCPCS code, J9332 is used on claims to report supply and administration of this therapeutic agent, supporting billing, utilization tracking, and payer coverage determinations for infusion- or injection-based care. Nationally, accurate use of HCPCS drug codes matters for payment integrity, clinical supply management, and monitoring uptake of newer biologic therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, expected payers, typical modifiers used with HCPCS drug codes, and guidance on where to find additional coding and coverage details. The publication summarizes benchmarking and policy-relevant topics such as payer coverage patterns, billing practices for injectable biologics, and documentation elements commonly required by major payers. Data not provided in the input (for example, precise payer fee schedules, associated taxonomies, or ICD-10 pairings) are noted as unavailable. The piece is intended for billing managers, revenue-cycle staff, and clinicians involved in administering and coding injectable biologic therapies.